JP5110314B2 - Sleep improving composition and sleep improving agent - Google Patents

Sleep improving composition and sleep improving agent Download PDF

Info

Publication number
JP5110314B2
JP5110314B2 JP2008513200A JP2008513200A JP5110314B2 JP 5110314 B2 JP5110314 B2 JP 5110314B2 JP 2008513200 A JP2008513200 A JP 2008513200A JP 2008513200 A JP2008513200 A JP 2008513200A JP 5110314 B2 JP5110314 B2 JP 5110314B2
Authority
JP
Japan
Prior art keywords
sleep
component
composition
improving
per
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008513200A
Other languages
Japanese (ja)
Other versions
JPWO2007125883A1 (en
Inventor
季未子 飛鋪
英明 岩崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lion Corp
Original Assignee
Lion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lion Corp filed Critical Lion Corp
Priority to JP2008513200A priority Critical patent/JP5110314B2/en
Publication of JPWO2007125883A1 publication Critical patent/JPWO2007125883A1/en
Application granted granted Critical
Publication of JP5110314B2 publication Critical patent/JP5110314B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

本発明は、就寝前に摂取することにより、優れた睡眠改善効果、特に深いノンレム睡眠時間の増加効果が得られる睡眠改善用組成物に関するものである。   The present invention relates to a composition for improving sleep, which is obtained by taking it before going to bed, whereby an excellent sleep improving effect, in particular, an effect of increasing deep non-REM sleep time can be obtained.

睡眠は脳に休息を与えている状態であり、高等動物にとっては単なる活動停止の時間ではなく、高度の生理機能に支えられた適応行動である。睡眠がうまくとれないと大脳の情報処理能力に悪い影響が出る。例えば、睡眠が不足すると感じる不快な気分や意欲のなさは、身体の不調というよりも大脳そのものの機能低下に起因し、大脳が休息を要求していることを意味する。しかし、単に長時間睡眠をとってもあまりプラスには働かず、質の良い睡眠、即ち深い眠り(ノンレム睡眠)、特に深睡眠(ノンレム睡眠の睡眠段階3,4)をとることが質の高い生活に結びつく。   Sleep is a state in which the brain is rested, and for higher animals, it is not just a cessation of activity, but an adaptive behavior supported by high physiological functions. If you don't sleep well, your brain's information processing ability will be adversely affected. For example, an unpleasant mood or lack of motivation to feel that sleep is lacking means that the cerebrum is demanding resting due to a decline in the function of the cerebrum rather than a malfunction of the body. However, simply sleeping for a long time does not work very positively, and good quality sleep, that is, deep sleep (non-REM sleep), especially deep sleep (sleep stages 3 and 4 of non-REM sleep) is a high quality life. Tie.

睡眠に関わる技術として、CoQ10(特許文献1:特開2005−325086号公報参照)、テアニン(特許文献2:特開2005−289948号公報参照)、塩酸ジフェンヒドラミン(特許文献3:特開2005−179311号公報)、バレリアーナ属植物又はその抽出物(特許文献4:特開2003−183174号公報)、ラベンダー油等(特許文献5:特開2000−355545号公報)等が提案されている。しかしながら、不眠の原因は様々であり、さらに優れた睡眠改善効果、特に深いノンレム睡眠(深睡眠)時間の増加効果が得られるものが望まれていた。なお、本発明に関連する先行技術文献としては下記が挙げられる。   As technologies relating to sleep, CoQ10 (Patent Document 1: JP 2005-325086 A), theanine (Patent Document 2: JP 2005-289948 A), diphenhydramine hydrochloride (Patent Document 3: JP 2005-179411 A). No. 4), Valeriana plants or extracts thereof (Patent Document 4: JP 2003-183174 A), lavender oil, etc. (Patent Document 5: JP 2000-355545 A) and the like have been proposed. However, there are various causes of insomnia, and it has been desired to have an excellent sleep improvement effect, in particular, an effect of increasing deep non-REM sleep (deep sleep) time. In addition, the following is mentioned as a prior art document relevant to this invention.

特開2005−325086号公報JP 2005-325086 A 特開2005−289948号公報JP 2005-289948 A 特開2005−179311号公報JP 2005-179111 A 特開2003−183174号公報JP 2003-183174 A 特開2000−355545号公報JP 2000-355545 A 特開2005−348656号公報JP 2005-348656 A 特開2003−284537号公報JP 2003-284537 A 特開2005−13146号公報JP 2005-13146 A

本発明は上記事情に鑑みなされたもので、優れた睡眠改善効果、特に深いノンレム睡眠(深睡眠)時間の増加効果が得られる組成物を提供することを目的とする。   This invention is made | formed in view of the said situation, and it aims at providing the composition which can obtain the outstanding sleep improvement effect, especially the increase effect of deep non-REM sleep (deep sleep) time.

本発明者は、γ−アミノ酪酸(GABA)等の(A)副交感神経機能を高める作用を有する成分と、酢酸等の(B)末梢血流の増加を促す作用を有する成分とを組み合わせることにより、それぞれ単独で用いた場合には得られない優れた睡眠改善効果、特に深いノンレム睡眠時間の増加効果が得られ、熟眠感が得られることを知見した。本発明は、深睡眠の阻害要因のうち、末梢組織への血液供給を改善することが重要であるとの仮定からなされたもので、後述するデータが示すように、従来、睡眠に効果があることが知られていた(A)成分に加えて抹消血流の増加を促す(B)成分とを組み合わせることによって、(A)成分のみでは得られない睡眠改善効果が得られたものである。   The present inventor combined (A) a component having an action of enhancing parasympathetic nerve function such as γ-aminobutyric acid (GABA) and (B) a component having an action of promoting peripheral blood flow such as acetic acid. It was found that an excellent sleep improvement effect that cannot be obtained when used alone, in particular, an effect of increasing deep non-REM sleep time, and a deep sleep feeling can be obtained. The present invention is based on the assumption that it is important to improve the blood supply to peripheral tissues among the disturbing factors of deep sleep. As shown in the data described later, the present invention is conventionally effective for sleep. In addition to the component (A) that has been known, the combination of the component (B) that promotes the increase in peripheral blood flow provides a sleep improvement effect that cannot be obtained by the component (A) alone.

従って、下記発明を提供する。
[1].(A)γ−アミノ酪酸及び/又はグリシンと、(B)トマト酢とを含有する組成物であって、1回の睡眠あたりの(A)成分の摂取量が10〜3000mg、(B)成分中の酢酸としての摂取量が50〜3000mgとなるように含有する組成物であって、(A)成分/(B)成分中の酢酸の質量比が1/0.08〜1/100であることを特徴とする睡眠改善用組成物。
[2].(A)成分がγ−アミノ酪酸である[1]記載の睡眠改善用組成物。
[3].(A)γ−アミノ酪酸と、(B’)プロアントシアニジンとを含有する睡眠改善用組成物。
[4].(A)成分の1回の睡眠あたりの摂取量が2〜3000mg、(B)成分の1回の睡眠あたりの摂取量が5〜1000mgである[]記載の睡眠改善用組成物。
[5].(A)成分/(B)成分の質量比が1/0.001〜1/500である[]又は[]記載の睡眠改善用組成物。
[6].さらに、鎮静作用を有する香料を含有する[1]〜[]のいずれかに記載の睡眠改善用組成物。
[7].鎮静作用を有する香料が、ラベンダー、カモミール、クラリセージ、マージョラム、ユーカリ及びローズウッドから選ばれる香料である[6]記載の睡眠改善用組成物。
[8].さらに、ビタミンB6及び/又はカルシウムを含有する[1]〜[]のいずれかに記載の睡眠改善用組成物。
[9].剤型がドリンク、濃縮液体、粉末、タブレット又はゼリーである[1]〜[]のいずれかに記載の睡眠改善用組成物。
[10].就寝前に摂取される[1]〜[]のいずれかに記載の睡眠改善用組成物。
[11].(A)γ−アミノ酪酸及び/又はグリシンと(B)トマト酢とを有効成分として含有する睡眠改善剤。
[12].1回の睡眠あたりの(A)成分の摂取量が10〜3000mg、(B)成分中の酢酸としての摂取量が50〜3000mgであって、(A)成分/(B)成分中の酢酸の質量比が1/0.08〜1/100である[11]記載の睡眠改善剤。
[13].(A)γ−アミノ酪酸と(B’)プロアントシアニジンとを有効成分として含有する睡眠改善剤。
[14].(A)成分の1回の睡眠あたりの摂取量が2〜3000mg、(B’)成分の1回の睡眠あたりの摂取量が5〜1000mgである[13]記載の睡眠改善剤。
[15].(A)成分/(B’)成分の質量比が1/0.001〜1/500である[13]又は[14]記載の睡眠改善剤。
Accordingly, the following invention is provided.
[1]. (A) A composition containing γ-aminobutyric acid and / or glycine , and (B) tomato vinegar , wherein the intake of (A) component per sleep is 10 to 3000 mg, (B) component It is a composition containing so that the intake as acetic acid in it may be 50-3000 mg, Comprising : The mass ratio of the acetic acid in (A) component / (B) component is 1 / 0.08-1 / 100 The composition for sleep improvement characterized by the above-mentioned.
[2]. (A) The composition for improving sleep according to [1], wherein the component is γ-aminobutyric acid.
[3]. A composition for improving sleep comprising (A) γ-aminobutyric acid and (B ′) proanthocyanidins.
[4]. The composition for improving sleep according to [ 3 ], wherein the intake amount per sleep of the component (A) is 2 to 3000 mg, and the intake amount of the component (B ) per sleep is 5 to 1000 mg.
[5]. The composition for improving sleep according to [ 3 ] or [ 4 ], wherein the mass ratio of (A) component / (B ) component is 1 / 0.001 to 1/500.
[6]. Furthermore, the composition for improving sleep according to any one of [1] to [ 5 ], further comprising a fragrance having a sedative effect.
[7]. The composition for improving sleep according to [6], wherein the fragrance having a sedative effect is a fragrance selected from lavender, chamomile, clary sage, marjoram, eucalyptus and rosewood.
[8]. Further comprises vitamin of B 6 and / or calcium [1] to sleep improvement composition according to any one of [7].
[9]. The composition for improving sleep according to any one of [1] to [ 8 ], wherein the dosage form is a drink, concentrated liquid, powder, tablet or jelly.
[10]. The composition for improving sleep according to any one of [1] to [ 9 ], which is taken before going to bed.
[11]. (A) A sleep improving agent containing γ-aminobutyric acid and / or glycine and (B) tomato vinegar as active ingredients.
[12]. The intake amount of component (A) per sleep is 10 to 3000 mg, the intake amount as acetic acid in component (B) is 50 to 3000 mg, and the amount of acetic acid in component (A) / component (B) The sleep improving agent according to [11], wherein the mass ratio is 1 / 0.08 to 1/100.
[13]. (A) A sleep improving agent containing γ-aminobutyric acid and (B ′) proanthocyanidins as active ingredients.
[14]. The sleep improving agent according to [13], wherein the intake amount per sleep of component (A) is 2 to 3000 mg, and the intake amount per sleep of component (B ′) is 5 to 1000 mg.
[15]. The sleep improving agent according to [13] or [14], wherein the mass ratio of component (A) / component (B ′) is 1 / 0.001 to 1/500.

本発明の睡眠改善用組成物によれば、優れた睡眠改善効果、特に深いノンレム睡眠時間を長くすることができ、起床時に満足な熟眠感を得ることができる。   According to the composition for improving sleep of the present invention, an excellent sleep improving effect, in particular, a deep non-REM sleep time can be lengthened, and a satisfactory sleep feeling can be obtained when waking up.

一般に睡眠中には「レム睡眠」と「ノンレム睡眠」が約90分を1単位として繰り返されており、眠りについてから約3時間の間に、深くぐっすりと眠っている状態である深いノンレム睡眠が集中する。睡眠障害の一つは、この深いノンレム睡眠がなくなり、あるいは短くなったりすることで、睡眠の質の低下につながっているといわれている。本発明の「睡眠改善」とは、特にこの深いノンレム睡眠の質及び時間を改善することで熟眠感を得、睡眠の質の向上に寄与しようというものである。   In general, “REM sleep” and “NREM sleep” are repeated for about 90 minutes as one unit during sleep, and deep non-REM sleep, which is a state of deep sleep, is about 3 hours after sleeping. concentrate. One of the sleep disorders is said to be due to the loss of sleep quality due to the disappearance or shortening of this deep non-REM sleep. The “sleep improvement” of the present invention is intended to contribute to the improvement of sleep quality by obtaining a deep sleep feeling by improving the quality and time of this deep non-REM sleep.

本発明の睡眠改善用組成物は、(A)副交感神経機能を高める作用を有する成分と、(B)末梢血流の増加を促す作用を有する成分とを、睡眠改善剤として含有する睡眠改善用組成物である。
(A)副交感神経機能を高める作用を有する好適な成分としては、γ−アミノ酪酸(GABA)、テアニン、トリプトファン及びグリシン等のアミノ酸が挙げられる。これらは1種単独で又は2種以上を適宜組み合わせて用いることができる。この中でもγ−アミノ酪酸が好ましい。γ−アミノ酪酸は、野菜や発芽玄米、お茶や発酵食品等一部の食品中に含まれている成分であり、脳内では神経伝達物質の一つとして神経興奮の抑制に関与している。
The composition for improving sleep of the present invention comprises (A) a component having an action of enhancing parasympathetic nerve function and (B) a component having an action of promoting an increase in peripheral blood flow as a sleep improving agent. It is a composition.
(A) As a suitable component which has the effect | action which raises a parasympathetic nerve function, amino acids, such as (gamma) -aminobutyric acid (GABA), theanine, tryptophan, and glycine, are mentioned. These can be used individually by 1 type or in combination of 2 or more types. Among these, γ-aminobutyric acid is preferable. γ-aminobutyric acid is a component contained in some foods such as vegetables, germinated brown rice, tea and fermented foods, and is involved in the suppression of nerve excitement as one of the neurotransmitters in the brain.

γ−アミノ酪酸の調製方法は特に限定されず、野菜、果物、穀類から抽出する方法、乳タンパクから乳酸菌発酵により得る方法、特開2005−239686号公報記載の方法等が挙げられる。   The preparation method of (gamma) -aminobutyric acid is not specifically limited, The method of extracting from vegetables, fruits, cereals, the method of obtaining from lactic acid bacteria fermentation from milk protein, the method of Unexamined-Japanese-Patent No. 2005-239686, etc. are mentioned.

(A)副交感神経機能を高める作用を有する成分の摂取量は、1回の睡眠あたり2〜3000mg、好ましくは2.2〜2500mg、より好ましくは2.4〜2000mg、さらに好ましくは2.5〜1500mgである。特に好ましくは10〜1500mgである。これに応じて睡眠改善用組成物中の配合量を適宜選定する。例えば、1回の睡眠あたり50mL摂取する組成物であれば、組成物50mL中に2〜3000mg配合すればよい。 (A) The intake amount of the component having the effect of enhancing the parasympathetic nerve function is 2 to 3000 mg, preferably 2.2 to 2500 mg, more preferably 2.4 to 2000 mg, and further preferably 2.5 to 2 per sleep. 1500 mg. Particularly preferred is 10 to 1500 mg. According to this, the compounding quantity in the composition for sleep improvement is selected suitably. For example, if it is a composition which ingests 50mL per one sleep, what is necessary is just to mix | blend 2-3000 mg in 50mL of a composition.

(B)末梢血流の増加を促す作用を有する好適な成分としては、酢酸、ポリフェノールが挙げられ、1種単独で又は2種以上を適宜組み合わせて用いることができる。この中でも特に酢酸が好ましい。酢酸としては、酢酸を使用してもよいし食酢として配合してもよいが、食酢を配合することが好ましい。食酢としては、例えば、米酢、リンゴ酢、ブルーベリー酢等の果実酢、野菜酢、粕酢、麦芽酢、アルコール酢、蒸留酢、濃縮酢、黒酢、もろみ酢、トマト酢、合成酢が挙げられるが、米酢、果実酢、野菜酢、粕酢、アルコール酢、トマト酢が好適であり、特にトマト酢が好ましい。   (B) As a suitable component which has the effect | action which accelerates | stimulates the increase in peripheral blood flow, an acetic acid and a polyphenol are mentioned, It can use individually by 1 type or in combination of 2 or more types. Of these, acetic acid is particularly preferred. As acetic acid, acetic acid may be used or vinegar may be blended, but vinegar is preferably blended. Examples of vinegar include fruit vinegar such as rice vinegar, apple vinegar, blueberry vinegar, vegetable vinegar, straw vinegar, malt vinegar, alcohol vinegar, distilled vinegar, concentrated vinegar, black vinegar, moromi vinegar, tomato vinegar, and synthetic vinegar. However, rice vinegar, fruit vinegar, vegetable vinegar, straw vinegar, alcohol vinegar, and tomato vinegar are preferred, and tomato vinegar is particularly preferred.

なお、トマト酢は、上記(A)成分のγ−アミノ酪酸と、(B)成分の酢酸とを含むものである。トマト酢に含まれるγ−アミノ酪酸の量は、トマトの種類、栽培時期、栽培場所、熟度等により異なるが、加工用トマトの搾汁液100g中には50mg前後、品種名「桃太郎」トマトには、トマト100g中約50〜140mg含まれているといわれている。   Note that tomato vinegar contains γ-aminobutyric acid as component (A) and acetic acid as component (B). The amount of γ-aminobutyric acid contained in tomato vinegar varies depending on the type of tomato, cultivation time, cultivation place, maturity, etc., but in 100 g of tomato juice for processing, about 50 mg, the variety name “Momotaro” tomato Is said to be contained in about 50 to 140 mg in 100 g of tomato.

酢酸を用いる場合、その摂取量は1回の睡眠あたり50〜3000mgが好ましく、より好ましくは80〜2000mg、より好ましくは120〜1500mgである。これに応じて睡眠改善用組成物中の配合量を適宜選定する。例えば、1回の睡眠あたり50mL摂取する組成物であれば、組成物50mL中に50〜3000mg配合すればよい。   When acetic acid is used, the intake is preferably 50 to 3000 mg, more preferably 80 to 2000 mg, and more preferably 120 to 1500 mg per sleep. According to this, the compounding quantity in the composition for sleep improvement is selected suitably. For example, if it is a composition which ingests 50mL per sleep, what is necessary is just to mix | blend 50-3000 mg in 50mL of compositions.

ポリフェノールとしてはフラボノイドが好ましく、フラボノイドとしては、カテキン、プロアントシアニジン、アントシアニン、アントシアニジン、フラボノール、イソフラボン等が挙げられる。この中でも、カテキン、プロアントシアニジン、アントシアニン、アントシアニジンが好ましい。これらは植物抽出物や果汁として配合でき、また精製されたものを使用してもよい。これらの成分が含まれる植物抽出物や果汁としては、具体的には、緑茶エキス、ブドウ種子エキス、松樹皮エキス、大豆エキス、黒豆エキス、ブドウ果汁、グランベリー果汁、ブルーベリー果汁、ビルベリー果汁、リンゴ果汁が好適である。   The polyphenol is preferably a flavonoid, and examples of the flavonoid include catechin, proanthocyanidins, anthocyanins, anthocyanidins, flavonols, isoflavones and the like. Among these, catechin, proanthocyanidins, anthocyanins, and anthocyanidins are preferable. These can be blended as plant extracts or fruit juices, or purified ones may be used. Specific examples of plant extracts and fruit juices containing these ingredients include green tea extract, grape seed extract, pine bark extract, soybean extract, black bean extract, grape juice, granberry juice, blueberry juice, bilberry juice, apple Fruit juice is preferred.

ポリフェノールを用いる場合、その摂取量は1回の睡眠あたり5〜1000mgが好ましく、より好ましくは10〜800mg、さらに好ましくは20〜600mgである。これに応じて睡眠改善用組成物中の配合量を適宜選定する。例えば、1回の睡眠あたり50mL摂取する組成物であれば、組成物50mL中に5〜1000mg配合すればよい。   When using polyphenol, the intake is preferably 5 to 1000 mg per sleep, more preferably 10 to 800 mg, and still more preferably 20 to 600 mg. According to this, the compounding quantity in the composition for sleep improvement is selected suitably. For example, if it is a composition ingested 50 mL per sleep, 5-1000 mg may be mix | blended in 50 mL of compositions.

(B)成分が酢酸の場合、(A)成分/(B)成分の質量比は1/0.01〜1/1000が好ましく、より好ましくは1/0.08〜1/800であり、さらに好ましくは1/2〜1/500、特に好ましくは1/2〜1/300であり、最も好ましくは1/2〜1/100である。1/0.01を超えると、末梢組織に血液が十分供給できない場合があり、1/1000未満だと、副交感神経系の活動が優位になりにくい場合がある。   When component (B) is acetic acid, the mass ratio of component (A) / component (B) is preferably 1 / 0.01 to 1/1000, more preferably 1 / 0.08 to 1/800, It is preferably 1/2 to 1/500, particularly preferably 1/2 to 1/300, and most preferably 1/2 to 1/100. If the ratio exceeds 1 / 0.01, blood may not be sufficiently supplied to peripheral tissues. If the ratio is less than 1/1000, the activity of the parasympathetic nervous system may not be dominant.

(B)成分がポリフェノールの場合、(A)成分/(B)成分の好適な質量比は1/0.001〜1/500であり、好ましくは1/0.001〜1/100、より好ましくは1/0.08〜1/90、さらに好ましくは1/0.1〜1/80である。また、下限は1/40がさらに好ましく、特に好ましくは1/20、最も好ましくは1/12である。1/0.001を超えると、末梢組織に血液が十分供給できない場合があり、1/500未満だと、副交感神経系の活動が優位になりにくい場合がある。   When the component (B) is polyphenol, the preferred mass ratio of the component (A) / component (B) is 1 / 0.001 to 1/500, preferably 1 / 0.001 to 1/100, more preferably Is 1 / 0.08 to 1/90, more preferably 1 / 0.1 to 1/80. Further, the lower limit is more preferably 1/40, particularly preferably 1/20, and most preferably 1/12. If the ratio exceeds 1 / 0.001, blood may not be sufficiently supplied to peripheral tissues. If the ratio is less than 1/500, the activity of the parasympathetic nervous system may not be dominant.

本発明の睡眠改善用組成物には、さらに鎮静作用を有する香料を1種単独で又は2種以上を適宜組み合わせて配合すると、より熟眠感を得ることができる。鎮静作用を有する香料としては、ラベンダー、カモミール、クラリセージ、マージョラム、ユーカリ、ローズウッド等が挙げられ、この中でもラベンダー、ユーカリが好適である。これら香料の1回の睡眠あたりの摂取量は0.001〜3000mgが好ましく、香料の強さによって適宜調整することが好ましい。   In the composition for improving sleep of the present invention, when a perfume having a sedative action is added alone or in combination of two or more, a deep sleep feeling can be obtained. Examples of the fragrance having a sedative effect include lavender, chamomile, clary sage, marjoram, eucalyptus, rosewood, etc. Among them, lavender and eucalyptus are preferable. The amount of these perfumes consumed per sleep is preferably 0.001 to 3000 mg, and is suitably adjusted according to the strength of the perfumes.

さらに、冷え性を伴う睡眠改善効果のさらなる向上のために、ビタミンやミネラル、上記鎮静作用を有する香料以外のフレーバー等を1種単独で又は2種以上を適宜組み合わせて配合することが好ましい。ビタミンとしては、ビタミンB1、B2、B6、B12、C、A、D、E、K、ナイアシン、葉酸、パントテン酸、ビオチン、ユビキノン、これらの各誘導体が挙げられる。この中でも、B1、B2、B6、B12、Cが好ましい。ビタミンの1回の睡眠あたりの摂取量及び睡眠改善用組成物中の配合量は、栄養機能食品の栄養素の配合限度量に従うのが好ましい。Furthermore, in order to further improve the sleep-improving effect with cooling properties, it is preferable to blend vitamins, minerals, flavors other than the fragrance having the sedative action, etc., alone or in combination of two or more. Examples of vitamins include vitamins B 1 , B 2 , B 6 , B 12 , C, A, D, E, K, niacin, folic acid, pantothenic acid, biotin, ubiquinone, and their respective derivatives. Among these, B 1, B 2, B 6, B 12, C is preferable. It is preferable that the intake amount of vitamin per sleep and the blending amount in the composition for improving sleep conform to the blending limit amount of nutrients of the nutritional functional food.

ミネラルとしては、カルシウム、鉄、リン、マグネシウム、カリウム、セレン、亜鉛等が挙げられる。ミネラルの1回の睡眠あたりの摂取量及び睡眠改善用組成物中の配合量は、栄養機能食品の栄養素の配合限度量に従うのが好ましい。ビタミンやミネラルとしては、ビタミンB6及び/又はカルシウムを用いることが好ましい。Examples of minerals include calcium, iron, phosphorus, magnesium, potassium, selenium, and zinc. It is preferable that the intake amount of the mineral per sleep and the blending amount in the composition for improving sleep conform to the blending limit amount of nutrients of the nutritional functional food. As vitamins and minerals, vitamin B 6 and / or calcium is preferably used.

フレーバーとしては、レモン、オレンジ、グレープフルーツ、ライム、マンダリン、タンジェリン、アップル、バナナ、チェリー、グレープ、メロン、ピーチ、ストロベリー、ミルク、クリーム、バター、チーズ、ヨーグルト、コーヒー、紅茶、緑茶、ウーロン茶、ココア、コーラ、バニラ、ペパーミント、スペアミント、シナモン、ナツメグ、ペパー、ガーリック、ジンジャー、クローブ、アーモンド、ピーナッツ、ヘーゼルナッツ、マカダミアナッツ、トマト、オニオン、ガーリック、セロリー、パセリ、イチゴ、ライチ等が挙げられる。   Flavors include lemon, orange, grapefruit, lime, mandarin, tangerine, apple, banana, cherry, grape, melon, peach, strawberry, milk, cream, butter, cheese, yogurt, coffee, tea, green tea, oolong tea, cocoa, Examples include cola, vanilla, peppermint, spearmint, cinnamon, nutmeg, pepper, garlic, ginger, clove, almond, peanut, hazelnut, macadamia nut, tomato, onion, garlic, celery, parsley, strawberry and lychee.

フレーバーを用いる場合、その摂取量は1回の睡眠あたり0.1mg〜1000mgが好ましい。   When using a flavor, the intake is preferably 0.1 mg to 1000 mg per sleep.

本発明の睡眠改善用組成物には、さらに、栄養成分の補助として、(A)及び(B)成分以外の植物エキス、発酵微生物、カロテノイド、カルニチン、食物繊維、不飽和脂肪酸、キチン・キトサン、プロポリス、コラーゲン、イソフラボン、乳酸菌やビフィズス菌等の発酵微生物等を配合してもよい。その他、食品に用いられる原材料なら制限なく使用でき、例えば、上記以外の香料、ソルビトール、マルチトール、ステビア抽出物、アスパルテーム、アセスルファムカリウム、スクラロース、パラチノース等の甘味料、クエン酸、酒石酸、酪酸、核酸等の酸味料、上記[0016]に記載の果汁を除く他の果汁等の矯味剤、賦型剤、pH調整剤、乳化剤、増粘剤、防腐剤、溶解補助剤、着色料、(A)成分以外のアミノ酸等が挙げられる。   In the composition for improving sleep of the present invention, as an auxiliary to nutritional components, plant extracts other than components (A) and (B), fermenting microorganisms, carotenoids, carnitines, dietary fibers, unsaturated fatty acids, chitin / chitosan, You may mix | blend fermentation microorganisms, such as propolis, collagen, isoflavone, lactic acid bacteria, and bifidobacteria. Other ingredients that can be used in foods can be used without limitation. Acidulants such as those other than fruit juices described in [0016] above, corrigents such as other fruit juices, excipients, pH adjusters, emulsifiers, thickeners, preservatives, solubilizers, colorants, (A) Examples include amino acids other than the components.

本発明の睡眠改善用組成物の剤型は、ドリンク(飲料)、濃縮液体、粉末、タブレット又はゼリー等にすることができ、剤型の常法に基づいて、例えば上記成分、必要に応じて水(残部)を混合して得ることができる。   The dosage form of the sleep improving composition of the present invention can be a drink (beverage), a concentrated liquid, a powder, a tablet, a jelly, or the like. It can be obtained by mixing water (remainder).

本発明の睡眠改善用組成物は就寝前に摂取されることが好ましく、より好ましくは就寝直前〜就寝120分前に摂取するとよい。   The composition for improving sleep of the present invention is preferably taken before going to bed, more preferably taken immediately before going to bed and 120 minutes before going to bed.

以下、実施例、参考例及び比較例を示し、本発明を具体的に説明するが、本発明は下記の実施例に制限されるものではない。 EXAMPLES Hereinafter, although an Example, a reference example, and a comparative example are shown and this invention is demonstrated concretely, this invention is not restrict | limited to the following Example.

[実施例1〜5、参考例1〜5、比較例1〜5]
表1〜4に示すドリンク剤組成物(50mL;1本)を調製し、下記方法に基づいて、深睡眠量、末梢血流改善効果、熟眠感について評価した。結果を表中に併記する。
[ Examples 1-5, Reference Examples 1-5, Comparative Examples 1-5]
The drink composition (50 mL; 1) shown in Tables 1-4 was prepared, and the deep sleep amount, the peripheral blood flow improvement effect, and the feeling of deep sleep were evaluated based on the following method. The results are also shown in the table.

(1)深睡眠量の測定
30代女性3人にドリンク剤組成物1本を就寝30分前に飲用してもらい、就寝中の脳波、眼球運動、筋電図、呼吸運動、心電図、酸素飽和度、下肢の動き等を終夜記録する終夜睡眠ポリグラフ検査を行い、睡眠の深さを解析した。測定には終夜睡眠ポリグラフ(フクダ電子製)を用いた。深睡眠量は、脳が休んでいる状態であるノンレム睡眠のステージ3及び4段階の合計時間とした。結果を平均値で示す。
(2)末梢血流改善効果の測定(血管幅の測定)
冷え性の女性5人にドリンク剤組成物1本を摂取してもらい、ドリンク剤組成物摂取前後の手指の血管幅を末梢血管モニタリング装置(シスメックス社製アストリムSU)で測定した。結果は、ドリンク剤組成物摂取前の末梢血管幅を100%としたときのドリンク剤組成物摂取後の末梢血管幅の%をドリンク剤組成物摂取前後の末梢血管幅変化率(%)とし、平均値で示す(n=5)。
(3)熟眠感の評価
30代の睡眠に不満をもつ女性10人を5人ずつ2群に分けて、一方の群は先に試験ドリンク剤組成物1本を就寝30分前に1週間摂取し、1週間間隔をあけてプラセボ1本を就寝30分前に1週間摂取した。もう一方の群は、先にプラセボ1本を就寝30分前に1週間摂取し、1週間間隔をあけて試験ドリンク剤組成物1本を就寝30分前に1週間摂取した。各被験者について、飲料摂取中の症状を下記の評価基準において評価した。結果を10人の平均値で示す。
〈評価基準〉
0:試験ドリンク剤組成物とプラセボとで熟眠感が変わらなかった。
1:プラセボに比べ試験ドリンク剤組成物を摂取した場合が、熟眠感がやや得られた。
2:プラセボに比べ試験ドリンク剤組成物を摂取した場合が、熟眠感が得られた。
(1) Measurement of deep sleep amount Three women in their 30s took one drink composition 30 minutes before bedtime, and EEG, eye movement, electromyogram, respiratory exercise, electrocardiogram, oxygen saturation during bedtime A polysomnographic examination was performed overnight to record the degree and movement of the lower limbs, and the depth of sleep was analyzed. An overnight polysomnograph (Fukuda Denshi) was used for the measurement. The amount of deep sleep was the total time of stages 3 and 4 of non-REM sleep, which is a state where the brain is resting. Results are shown as average values.
(2) Measurement of peripheral blood flow improvement effect (measurement of blood vessel width)
Five cold women were allowed to take one drink composition, and the blood vessel width of the fingers before and after taking the drink composition was measured with a peripheral blood vessel monitoring device (Astrim SU manufactured by Sysmex Corporation). As a result, the percentage of peripheral blood vessel width after ingesting the drink composition when the peripheral blood vessel width before ingesting the drink composition is taken as 100% is the rate of change in peripheral blood vessel width (%) before and after ingestion of the drink composition, The average value is shown (n = 5).
(3) Evaluation of a feeling of deep sleep 10 women who are dissatisfied with sleep in their 30s are divided into 2 groups of 5 each, and one group takes 1 test drink composition at 30 minutes before bedtime for 1 week. Then, one placebo was taken for one week 30 minutes before going to bed at an interval of one week. In the other group, one placebo was previously taken for 30 minutes before bedtime for 1 week, and one test drink composition was taken for 1 week 30 minutes before bedtime at an interval of 1 week. For each subject, symptoms during drinking were evaluated according to the following evaluation criteria. A result is shown by the average value of 10 persons.
<Evaluation criteria>
0: The feeling of deep sleep did not change between the test drink composition and the placebo.
1: Compared with placebo, a slightly sleepy feeling was obtained when the test drink composition was ingested.
2: A feeling of deep sleep was obtained when the test drink composition was ingested compared to placebo.

Figure 0005110314
Figure 0005110314

Figure 0005110314
Figure 0005110314

Figure 0005110314
Figure 0005110314

Figure 0005110314
Figure 0005110314

[実施例6〜9
表5に示す組成の睡眠改善用ドリンクを、トマト酢、L−カルニチン、グルコン酸カルシウム、ニコチン酸アミド、ビタミン類、果汁、甘味料、保存料及び着色料を混合溶解し、その後、予め水に分散させたγ−アミノ酪酸を配合し、さらに香料、残りの水を加えて混合溶解してろ過し、滅菌充填して調製した。これらの睡眠改善用ドリンクはいずれも良好な睡眠改善効果を示した。
[Examples 6 to 9 ]
A drink for improving sleep having the composition shown in Table 5 is prepared by mixing and dissolving tomato vinegar, L-carnitine, calcium gluconate, nicotinamide, vitamins, fruit juice, sweetener, preservative and colorant, and then preliminarily added to water. Dispersed γ-aminobutyric acid was added, and a fragrance and the remaining water were added, mixed and dissolved, filtered, and sterilized to prepare. All of these drinks for improving sleep showed a good sleep improving effect.

Figure 0005110314
Figure 0005110314

[実施例10
ゼリー剤
グラニュー糖50質量部、スクラロース0.02質量部、水飴50質量部、オレンジ果汁100質量部、水480質量部、カラギナン5質量部、ローカストビーンガム5質量部、クエン酸ナトリウム1.2質量部、香料1.5質量部、γ−アミノ酪酸5質量部、トマト酢12質量部(酢酸換算0.6質量部)、グルコン酸カルシウム1質量部、ビタミンB20.02質量部、ビタミンB60.02質量部、ビタミンC0.2質量部、乳化剤0.8質量部を加熱溶解した。次いで、型に流し込み、一夜静置することにより、ゼリーを得た。このゼリー剤は良好な睡眠改善効果を示した。
[Example 10 ]
Jelly agent 50 parts by weight of granulated sugar, 0.02 part by weight of sucralose, 50 parts by weight of starch syrup, 100 parts by weight of orange juice, 480 parts by weight of water, 5 parts by weight of carrageenan, 5 parts by weight of locust bean gum, 1.2 parts by weight of sodium citrate Parts, fragrance 1.5 parts by weight, γ-aminobutyric acid 5 parts by weight, tomato vinegar 12 parts by weight (acetic acid equivalent 0.6 parts by weight), calcium gluconate 1 part by weight, vitamin B 2 0.02 parts by weight, vitamin B 6 0.02 parts by mass, 0.2 parts by mass of vitamin C, and 0.8 parts by mass of an emulsifier were dissolved by heating. Then, it was poured into a mold and left overnight to obtain a jelly. This jelly agent showed a good sleep improving effect.

Claims (15)

(A)γ−アミノ酪酸及び/又はグリシンと、(B)トマト酢とを含有する組成物であって、1回の睡眠あたりの(A)成分の摂取量が10〜3000mg、(B)成分中の酢酸としての摂取量が50〜3000mgとなるように含有する組成物であって、(A)成分/(B)成分中の酢酸の質量比が1/0.08〜1/100であることを特徴とする睡眠改善用組成物。(A) A composition containing γ-aminobutyric acid and / or glycine , and (B) tomato vinegar , wherein the intake of (A) component per sleep is 10 to 3000 mg, (B) component It is a composition containing so that the intake as acetic acid in it may be 50-3000 mg, Comprising : The mass ratio of the acetic acid in (A) component / (B) component is 1 / 0.08-1 / 100 The composition for sleep improvement characterized by the above-mentioned. (A)成分がγ−アミノ酪酸である請求項1記載の睡眠改善用組成物。The composition for improving sleep according to claim 1, wherein the component (A) is γ-aminobutyric acid. (A)γ−アミノ酪酸と、(B’)プロアントシアニジンとを含有する睡眠改善用組成物。A composition for improving sleep comprising (A) γ-aminobutyric acid and (B ′) proanthocyanidins. (A)成分の1回の睡眠あたりの摂取量が2〜3000mg、(B)成分の1回の睡眠あたりの摂取量が5〜1000mgである請求項記載の睡眠改善用組成物。The composition for improving sleep according to claim 3 , wherein the intake amount per sleep of the component (A) is 2 to 3000 mg, and the intake amount per sleep of the component (B ' ) is 5 to 1000 mg. (A)成分/(B)成分の質量比が1/0.001〜1/500である請求項又は記載の睡眠改善用組成物。The sleep improving composition according to claim 3 or 4, wherein the mass ratio of (A) component / (B ' ) component is 1 / 0.001 to 1/500. さらに、鎮静作用を有する香料を含有する請求項1〜のいずれか1項記載の睡眠改善用組成物。Furthermore, the composition for sleep improvement of any one of Claims 1-5 containing the fragrance | flavor which has a sedative effect. 鎮静作用を有する香料が、ラベンダー、カモミール、クラリセージ、マージョラム、ユーカリ及びローズウッドから選ばれる香料である請求項6記載の睡眠改善用組成物。The composition for improving sleep according to claim 6, wherein the fragrance having a sedative action is a fragrance selected from lavender, chamomile, clary sage, marjoram, eucalyptus and rosewood. さらに、ビタミンB6及び/又はカルシウムを含有する請求項1〜のいずれか1項記載の睡眠改善用組成物。Furthermore, any one sleep improvement composition according to claim 1-7, containing a vitamin of B 6 and / or calcium. 剤型がドリンク、濃縮液体、粉末、タブレット又はゼリーである請求項1〜のいずれか1項記載の睡眠改善用組成物。The composition for sleep improvement according to any one of claims 1 to 8 , wherein the dosage form is a drink, concentrated liquid, powder, tablet or jelly. 就寝前に摂取される請求項1〜のいずれか1項記載の睡眠改善用組成物。The composition for improving sleep according to any one of claims 1 to 9 , which is taken before going to bed. (A)γ−アミノ酪酸及び/又はグリシンと(B)トマト酢とを有効成分として含有する睡眠改善剤。(A) A sleep improving agent containing γ-aminobutyric acid and / or glycine and (B) tomato vinegar as active ingredients. 1回の睡眠あたりの(A)成分の摂取量が10〜3000mg、(B)成分中の酢酸としての摂取量が50〜3000mgであって、(A)成分/(B)成分中の酢酸の質量比が1/0.08〜1/100である請求項11記載の睡眠改善剤。The intake amount of component (A) per sleep is 10 to 3000 mg, the intake amount as acetic acid in component (B) is 50 to 3000 mg, and the amount of acetic acid in component (A) / component (B) The sleep improving agent according to claim 11, wherein the mass ratio is 1 / 0.08 to 1/100. (A)γ−アミノ酪酸と(B’)プロアントシアニジンとを有効成分として含有する睡眠改善剤。(A) A sleep improving agent containing γ-aminobutyric acid and (B ′) proanthocyanidins as active ingredients. (A)成分の1回の睡眠あたりの摂取量が2〜3000mg、(B’)成分の1回の睡眠あたりの摂取量が5〜1000mgである請求項13記載の睡眠改善剤。The sleep improving agent according to claim 13, wherein the intake amount per sleep of the component (A) is 2 to 3000 mg, and the intake amount of the component (B ') per sleep is 5 to 1000 mg. (A)成分/(B’)成分の質量比が1/0.001〜1/500である請求項13又は14記載の睡眠改善剤。The sleep improving agent according to claim 13 or 14, wherein the mass ratio of the component (A) / the component (B ') is 1 / 0.001 to 1/500.
JP2008513200A 2006-04-28 2007-04-24 Sleep improving composition and sleep improving agent Active JP5110314B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008513200A JP5110314B2 (en) 2006-04-28 2007-04-24 Sleep improving composition and sleep improving agent

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006125178 2006-04-28
JP2006125178 2006-04-28
PCT/JP2007/058784 WO2007125883A1 (en) 2006-04-28 2007-04-24 Composition for improvement in sleep quality
JP2008513200A JP5110314B2 (en) 2006-04-28 2007-04-24 Sleep improving composition and sleep improving agent

Publications (2)

Publication Number Publication Date
JPWO2007125883A1 JPWO2007125883A1 (en) 2009-09-10
JP5110314B2 true JP5110314B2 (en) 2012-12-26

Family

ID=38655409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008513200A Active JP5110314B2 (en) 2006-04-28 2007-04-24 Sleep improving composition and sleep improving agent

Country Status (2)

Country Link
JP (1) JP5110314B2 (en)
WO (1) WO2007125883A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4773502B2 (en) * 2008-11-27 2011-09-14 株式会社 伊藤園 Container-packed vinegar beverages for warming and chilling improvers
JP2011051970A (en) * 2009-08-07 2011-03-17 Kose Corp Perfume composition for use in sleep improvement, and cosmetic containing the same, and method for improving sleep
JP5585075B2 (en) * 2009-12-24 2014-09-10 ライオン株式会社 Growth hormone secretagogue
JP2014172892A (en) * 2013-03-12 2014-09-22 Fujifilm Corp Sleep improvement agent, non-rem sleep period increasing agent and sedative agent
JP6665099B2 (en) * 2014-08-29 2020-03-13 わかもと製薬株式会社 Lactic acid bacteria-containing composition
JP7037161B2 (en) * 2016-07-07 2022-03-16 株式会社東洋新薬 Oral composition
EP3868215A4 (en) * 2018-10-16 2022-07-27 Nippon Chemiphar Co., Ltd. Agent for improving quality of sleep
JP6931012B2 (en) * 2019-01-21 2021-09-01 台灣中油股▲ふん▼有限公司 Cooking method with high production of γ-aminobutyric acid
JP6863637B1 (en) * 2020-07-01 2021-04-21 株式会社東洋新薬 Composition for improving sleep
WO2024142285A1 (en) * 2022-12-27 2024-07-04 フジッコ株式会社 Sleep improving agent

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001316256A (en) * 2000-04-28 2001-11-13 Taiyo Kagaku Co Ltd Composition for ameliorating blood flow
JP2003009820A (en) * 2001-07-05 2003-01-14 Hosoda Shoten:Kk Auxiliary food ingredient and food added with the auxiliary food ingredient
JP2003183174A (en) * 2001-12-19 2003-07-03 Fancl Corp Composition for insomnia
JP2003533547A (en) * 2000-05-26 2003-11-11 ハドソン,スーザン,ピー Plant-derived tryptophan source and use thereof
JP2005000040A (en) * 2003-06-10 2005-01-06 Nanto Shuhan Kk Moromi-su processed product and method for producing the same
JP2005082495A (en) * 2003-09-04 2005-03-31 Pharma Foods International Co Ltd Cerebral cell-protecting composition
WO2005067738A1 (en) * 2004-01-14 2005-07-28 Ajinomoto Co., Inc. Glycine-containing food and use thereof
JP2005198645A (en) * 2003-05-22 2005-07-28 Lion Corp Fermented liquid of tomato, hypotensive agent, method for producing the same, and eating and drinking composition
JP2005239694A (en) * 2004-02-27 2005-09-08 Taiyo Kagaku Co Ltd Anti-stress composition
JP2005245419A (en) * 2004-03-04 2005-09-15 Hideyo Sasaya Healthy food
JP2005289948A (en) * 2004-04-06 2005-10-20 Taiyo Kagaku Co Ltd Sleep improvement composition
WO2005097101A1 (en) * 2004-04-06 2005-10-20 Taiyokagaku Co., Ltd. Sleep-improving composition
JP2006061089A (en) * 2004-08-27 2006-03-09 Pharma Foods International Co Ltd Functional mayonnaise-like seasoning or dressing
JP2006158330A (en) * 2004-12-09 2006-06-22 Kazuhiro Kotani Health food containing black soybean skin and method for producing the same
JP2007238520A (en) * 2006-03-09 2007-09-20 Ueda Holdings:Kk Health food and supplement for sleep-inducement

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001316256A (en) * 2000-04-28 2001-11-13 Taiyo Kagaku Co Ltd Composition for ameliorating blood flow
JP2003533547A (en) * 2000-05-26 2003-11-11 ハドソン,スーザン,ピー Plant-derived tryptophan source and use thereof
JP2003009820A (en) * 2001-07-05 2003-01-14 Hosoda Shoten:Kk Auxiliary food ingredient and food added with the auxiliary food ingredient
JP2003183174A (en) * 2001-12-19 2003-07-03 Fancl Corp Composition for insomnia
JP2005198645A (en) * 2003-05-22 2005-07-28 Lion Corp Fermented liquid of tomato, hypotensive agent, method for producing the same, and eating and drinking composition
JP2005000040A (en) * 2003-06-10 2005-01-06 Nanto Shuhan Kk Moromi-su processed product and method for producing the same
JP2005082495A (en) * 2003-09-04 2005-03-31 Pharma Foods International Co Ltd Cerebral cell-protecting composition
WO2005067738A1 (en) * 2004-01-14 2005-07-28 Ajinomoto Co., Inc. Glycine-containing food and use thereof
JP2005239694A (en) * 2004-02-27 2005-09-08 Taiyo Kagaku Co Ltd Anti-stress composition
JP2005245419A (en) * 2004-03-04 2005-09-15 Hideyo Sasaya Healthy food
JP2005289948A (en) * 2004-04-06 2005-10-20 Taiyo Kagaku Co Ltd Sleep improvement composition
WO2005097101A1 (en) * 2004-04-06 2005-10-20 Taiyokagaku Co., Ltd. Sleep-improving composition
JP2006061089A (en) * 2004-08-27 2006-03-09 Pharma Foods International Co Ltd Functional mayonnaise-like seasoning or dressing
JP2006158330A (en) * 2004-12-09 2006-06-22 Kazuhiro Kotani Health food containing black soybean skin and method for producing the same
JP2007238520A (en) * 2006-03-09 2007-09-20 Ueda Holdings:Kk Health food and supplement for sleep-inducement

Also Published As

Publication number Publication date
WO2007125883A1 (en) 2007-11-08
JPWO2007125883A1 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
JP5110314B2 (en) Sleep improving composition and sleep improving agent
JP3907964B2 (en) Mental fatigue reducing composition, concentration maintenance enhancing composition and mental vitality maintenance enhancing composition
JP2006526398A (en) Weight control beverage
MXPA06012501A (en) Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite.
JP2008061511A (en) Flavor-improving agent, flavor-improving method using the flavor-improving agent, and food and drink
KR20090037403A (en) Senescence inhibitor
JP2008063321A (en) Muscle ageing inhibitor
JP6208604B2 (en) Body fat reducing agent
CN101484157A (en) Agent for improving muscle power
AU2002305703A1 (en) Carbohydrate modifying agent and drinks containing the modifying agent
EP1404351A1 (en) Carbohydrate modifying agent and drinks containing the modifying agent
JP2008063318A (en) Aging inhibitor
JP2008031148A (en) Agent for improving muscle power
JP2004262927A (en) Serum cholesterol-reducing agent, food or drink, and method for producing the same
JP6756395B2 (en) Beverage
JP2006028051A (en) Ameliorant for exhausted feeling at time of rising, composition for ameliorating exhausted feeling at time of rising, and food and beverage for ameliorating exhausted feeling at time of rising, containing them
JP2010111608A (en) Muscle damage inhibitor
JP2005139135A (en) Prophylactic and ameliorating agent of menopausal disorder
JP2011006355A (en) Composition and food and drink for improving bone density
JP4141271B2 (en) Citrus extract composition
JP2008031080A (en) Lipid utilization-promoting composition
JP2004215578A (en) Composition for health food product and health food product or health beverage product
JP2009023948A (en) Dopamine-inhibiting agent
KR20240092706A (en) Composition for promoting and improving sleep for solid food and jelly, and manufacturing method thereof
JP2009155291A (en) Hair-growing agent for preventing stress-related depilation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120912

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120925

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151019

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5110314

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350